Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460950 | 0.88 | ALDH1A1 (0.41) | NPC1CXCR2KDM4EALDH1A1LMNA | |
| SCHEMBL29032452 | 0.85 | MAPT (0.41) | MAPTNPC1MAOBMAOAALDH1A1 | |
| SCHEMBL19717306 | 0.79 | MAPT (0.69) | MAPTNPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5466776 | 0.79 | THRB (0.51) | MAPTNPC1MAOBMAOAKDM4E | |
| SCHEMBL4831046 | 0.79 | KDM4E (0.47) | MAPTMAOBMAOAKDM4EALDH1A1 | |
| SCHEMBL6420140 | 0.78 | S1PR4 (0.47) | MAPTNPC1KDM4EALDH1A1LMNA | |
| SCHEMBL27170273 | 0.78 | THRA (0.41) | MAPTNPC1LMNATHRBTHRA | |
| SCHEMBL4830826 | 0.78 | ALDH1A1 (0.46) | MAPTNPC1MAOBMAOAKDM4E | |
| SCHEMBL4843634 | 0.78 | ALDH1A1 (0.46) | MAPTNPC1MAOBMAOAKDM4E | |
| SCHEMBL10145035 | 0.78 | MAPT (0.49) | MAPTNPC1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | MAPT 758/4885NPC1 1089/4885MAOB 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.